Replies to post #430931 on Anavex Life Sciences Corp (AVXL)

[georgejjl]

PURE NINSENSE!!!

I should state that I've also come across a hypothesis that the brain volume loss from MABs comes directly from the loss of plaque itself (I suppose in contrast to loss of neurons), and so is not a bad thing.

GOD bless,

[Investor2014]

It would be interesting to know if the Anavex "MRI revealed significant reduction in brain volume loss, including whole brain (P = 0.0005)" also in addition reduced amyloid plaque.

I should state that I've also come across a hypothesis that the brain volume loss from MABs comes directly from the loss of plaque itself (I suppose in contrast to loss of neurons), and so is not a bad thing. It may have been a Saabagh piece where I read that. (I'm not saying I subscribe to that hypothesis.)

We won't get to know that from the P2a/3 trial since PET scans was not part of the protocol. Although not part of the clinicaltrials.gov record, I suppose Anavex may have requested PET scans at least for some patients in the OLE study.

As a side note interesting that the two OLE secondary outcome measures are ADAS- and ADCS-ADL, where ADL might provide more and perhaps better insights over longer term. Although of course not against placebo but with either OLE start of P2b/3 start or EOT as baseline.

[Hoskuld]

Joseph, there is significant brain volume loss with no mab therapy: https://www.alzforum.org/news/research-news/brain-changes-speak-volumes-about-normal-aging-and-dementia#:~:text=Although%20he%20found%20that%20hippocampal,1%20percent%2C%22%20he%20noted.

mAb therapy results in 28% greater loss than placebo: https://www.science.org/content/article/promising-alzheimer-s-therapy-and-related-drugs-shrink-brains

By contrast, 2-73 has greater efficacy, is much safer and has much less brain volume loss.